Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
By M. Genovese, J. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, C. Birbara, J. Box, K. Natarajan, I. Nuamah and 4 more. New England Journal of Medicine, 2005
1,228 citations recorded by the source corpus.
Subfields: Hematology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/2e5a6ba84aab677642c663498fa797dccda9e78a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Rheumatology
Citations in the corpus
- Cytokines in the pathogenesis of rheumatoid arthritis (2007, background): “However, some therapeutic benefit has been seen in patients treated with the fusion protein CTLA4–immunoglobulin Fc, which supports a role for T-cell co-stimulation and effector T-cell activation in rheumatoid arthriti”
- CD28 costimulation: from mechanism to therapy (2016, background): “The CTLA4Ig drugs have proven efficacy in ameliorating symptoms in rheumatoid arthritis (Genovese et al., 2005) and juvenile idiopathic arthritis (Ruperto et al., 2008, 2010), as well as in Immunity 44, May 17, 2016 981 prevention of acute rejection of renal transplants (Vincenti et al., 2005,…”
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, neutral): “There is high-level evidence from one RCT each that abatacept, golimumab, rituximab and tocilizumab are effective in patients for whom TNF inhibitor therapy has failed 97–100 (level 1b, grade A).”
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial (2008, background): “Other placebo-controlled studies of patients with rheumatoid arthritis have evaluated efficacy after patients switched from TNF inhibitors to drugs with other mechanisms of action (for example, abatacept and rituximab) (25, 26).”